Trial · NCT03951415
Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer
NCT03951415, Phase 2, Unknown, Leiden University Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer. Trials, record NCT03951415. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03951415
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer
- NCT number
- NCT03951415
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 55 participants, actual
- Lead sponsor
- Leiden University Medical Center
- Conditions
- Endometrial Neoplasms, Uterine Neoplasms, Endometrium Cancer
- Interventions
- PARP inhibitor and Anti-PD-L1
- First posted
- 2019-05-15
- Last updated
- 2021-04-01
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression free survival (PFS) | 6 months | PFS will be counted from the date of registration until the first observation of radiological progressive disease according to RECIST 1.1 criteria or death due to any cause, whichever occurred first. |
| Secondary | Objective response rate (ORR) | 12 weeks | according to RECIST 1.1 criteria |
| Secondary | Overall survival (OS) | Through study completion, up to 36 months | OS will be determined from the date of registration until death from any cause. |
| Secondary | Adverse events | Through study completion, up to 36 months | Assessed by NCI Common Terminology Criteria for adverse Events (CTCAE) version 5.0 |
| Secondary | Predictive biomarkers in tumor biopsy | At baseline | MMRd/POLE, HR status, quantification of CD3,CD4,CD8,CD103,CD161,PD-1,LAG3,CTLA-4,NKG2A,GOXp3 positieve T cells, NK cells, percentage PD-L1 on myeloid cells/tumorcells, quantification of myeloid cell infiltration (CD68,CD14,CD33,CD163) in tumor biopsies. |
| Other | Functional HRD assay (optional) | At baseline | Extra biopsy |
| Other | Immunological effects of PARP-1 inhibition (optional) | Change From Baseline to 6 weeks and 12 weeks | Tests for T cell and APC functionality measured by the measurement of recall antigen responses and mixed lymphocyte cultures, respectively, the levels of regulatory T cells, activation markers on T cells and DC). |
| Other | Predictive biomarkers for PD-L1 blocking in blood (optional) | Change From Baseline to 6 weeks and 12 weeks | e.g. monocyticMDSC levels, DC levels, inhibitory marker expression, neutrophil-to-lymphocyte ratio, absolute lymphocyte count, T-cell reactivity during PD-L1 blocking, T-cell cytokine expression after SEB activation |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03951415
GET https://conductscience.org/api/trials/v1/NCT03951415/registered